CRISPR/Cas9基因组编辑技术在HIV-1感染治疗中的应用进展

doi:10.16288/j.yczz.15-284

[an error occurred while processing this directive]

HEREDITAS(Beijing) ›› 2016, Vol. 38 ›› Issue (1): 9-16.doi: 10.16288/j.yczz.15-284

• Reviews • Previous Articles Next Articles

Application progress of CRISPR/Cas9 genome editing technology in the treatment of HIV-1 infection

Yinglun Han^{1, 2}, Qingwei Li^{1, 2}

1. College of Life Science, Liaoning Normal University, Dalian 116029, China;
2. Lamprey Research Center, Liaoning Normal University, Dalian 116029, China

Received:2015-06-19 Revised:2015-09-07 Online:2016-01-20 Published:2016-01-20
Supported by:
[Supported by grants from the National Program on Key Basic Research Project (973 Program) (No; 2013CB835304), the National Marine Public Projects (No; 201305016), the National Natural Science Foundation of China (General Program) (Nos; 31170353, 31202020, 31271323), and Dalian Science and Technology Program (No; 2013E11SF056)]

Abstract

Abstract: The goal of gene therapy is to introduce foreign genes into human target cells in a certain way to correct or compensate diseases caused by defective or abnormal genes. Therefore, gene therapy has great practical significance in studying the treatment of persistent or latent HIV-1 infection. At present, the existing methods of gene therapy have some major defects such as limited target site recognition and high frequency of off-targets. The latest research showed that the clustered regularly interspaced short palindromic repeats (CRISPR) /CRISPR-associated nuclease 9 (Cas9) system from bacteria and archaea has been successfully reformed to a targeted genome editing tool. Thus, how to achieve the goal of treating HIV-1 infection by modifying targeted HIV-1 virus genome effectively using the CRISPR/Cas9 system has become a current research focus. Here we review the latest achievements worldwide and briefly introduce applications of the CRISPR/Cas9 genome editing technology in the treatment of HIV-1 infection, including CCR5 gene editing, removal of HIV-1 virus and activation of HIV-1 virus, in order to provide reference for the prevention and treatment of HIV-1 infection.

Key words: CRISPR /Cas9, Human immunodeficiency virus, genome editing

Yinglun Han, Qingwei Li. Application progress of CRISPR/Cas9 genome editing technology in the treatment of HIV-1 infection[J]. HEREDITAS(Beijing), 2016, 38(1): 9-16.

References

[1] Saayman S, Ali SA, Morris KV, Weinberg MS. The therapeutic application of CRISPR/Cas9 technologies for HIV. Expert Opin Biol Ther , 2015, 15(6): 819-830.
[2] Yin LJ, Hu SQ, Guo F. The application of CRISPR-Cas9 gene editing technology in viral infection diseases. Hereditas(Beijing) , 2015, 37(5): 412-418. 殷利眷, 胡斯奇, 郭斐. CRISPR-Cas9基因编辑技术在病毒感染疾病治疗中的应用. 遗传, 2015, 37(5): 412-418.
[3] Gaj T, Gersbach CA, Barbas III CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol , 2013, 31(7): 397-405.
[4] Cai M, Yang Y. Targeted genome editing tools for disease modeling and gene therapy. Curr Gene Ther , 2014, 14(1): 2-9.
[5] DiGiusto DL, Krishnan A, Li LJ, Li HT, Li S, Rao A, Mi S, Yam P, Stinson S, Kalos M, Alvarnas J, Lacey SF, Yee JK, Li MJ, Couture L, Hsu D, Forman SJ, Rossi JJ, Zaia JA. RNA-based gene therapy for HIV with lentiviral vector-modified CD34 + cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med , 2010, 2(36): 36RA43.
[6] Hao YZ, Teng ZP, Zeng Y. HIV gene therapy overview and the latest developments. Chinese J Exp Clin Virol , 2013, 27(2): 156-158. 郝彦哲, 滕智平, 曾毅. HIV基因治疗概况及最新进展. 中华实验和临床病毒学杂志, 2013, 27(2): 156-158.
[7] Tian YR, Jiao YM, Zhang T, Wu H. Recent progress in the gene therapies against HIV-1. J Cap Med Univ , 2014, 35(1): 101-107. 田雅茹, 焦艳梅, 张彤, 吴昊. 抗HIV-1基因治疗新进展. 首都医科大学学报, 2014, 35(1): 101-107.
[8] Chung J, Scherer LJ, Gu A, Gardner AM, Torres-Coronado M, Epps EW, DiGiusto DL, Rossi JJ. Optimized lentiviral vectors for HIV gene therapy: multiplexed expression of small RNAs and inclusion of MGMT P140K drug resistance gene. Mol Ther , 2014, 22(5): 952-963.
[9] Mojica FJ, Díez-Villaseñor C, García-Martínez J, Almendros C. Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology , 2009, 155(Pt 3): 733-740.
[10] Mojica FJM, Díez-Villaseñor C, García-Martínez J, Soria E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol , 2005, 60(2): 174-182.
[11] Strong CL, Guerra HP, Mathew KR, Roy N, Simpson LR, Schiller MR. Damaging the integrated HIV proviral DNA with TALENs. PLoS One , 2015, 10(5): e0125652.
[12] Ye L, Wang JM, Beyer AI, Teque F, Cradick TJ, Qi ZX, Chang JC, Bao G, Muench MO, Yu JW, Levy JA, Kan YW. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA , 2014, 111(26): 9591-9596.
[13] Yi G, Choi JG, Bharaj P, Abraham S, Dang Y, Kafri T, Alozie O, Manjunath MN, Shankar P. CCR5 gene editing of resting CD4 + T cells by transient ZFN expression from HIV envelope pseudotyped nonintegrating lentivirus confers HIV-1 resistance in humanized mice. Mol Ther Nucleic Acids , 2014, 3: e198.
[14] Ru RN, Yao YC, Yu SL, Yin BP, Xu WW, Zhao ST, Qin L, Chen XP. Targeted genome engineering in human induced pluripotent stem cells by penetrating TALENs. Cell Regen (Lond) , 2013, 2(1): 5.
[15] Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science , 2012, 337(6096): 816-821.
[16] Cong L, Ran FA, Cox D, Lin SL, Barretto R, Habib N, Hsu PD, Wu XB, Jiang WY, Marraffini LA, Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science , 2013, 339(6121): 819-823.
[17] Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. RNA-programmed genome editing in human cells. Elife , 2013, 2: e00471.
[18] Mali P, Yang LH, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA-guided human genome engineering via Cas9. Science , 2013, 339(6121): 823-826.
[19] Gilbert LA, Larson MH, Morsut L, Liu ZR, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Doudna JA, Lim WA, Weiss

Metrics

Comments

www.chinagene.cn
备案号：京ICP备09063187号

Application progress of CRISPR/Cas9 genome editing technology in the treatment of HIV-1 infection

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Xiaoping Lian, Guangfu Huang, Yujiao Zhang, Jing Zhang, Fengyi Hu, Shilai Zhang. The discovery and utilization of favorable genes in Oryza longistaminata [J]. Hereditas(Beijing), 2023, 45(9): 765-780.
[2]	Zhongsheng Wu, Yu Gao, Yongtao Du, Song Dang, Kangmin He. The protocol of tagging endogenous proteins with fluorescent tags using CRISPR-Cas9 genome editing [J]. Hereditas(Beijing), 2023, 45(2): 165-175.
[3]	Meizhen Liu, Liren Wang, Yongmei Li, Xueyun Ma, Honghui Han, Dali Li. Generation of genetically modified rat models via the CRISPR/Cas9 technology [J]. Hereditas(Beijing), 2023, 45(1): 78-87.
[4]	Haitao Wang, Tingting Li, Xun Huang, Runlin Ma, Qiuyue Liu. Application of genetic modification technologies in molecular design breeding of sheep [J]. Hereditas(Beijing), 2021, 43(6): 580-600.
[5]	Xia Li, Wan Shi, Lizhao Geng, Jianping Xu. Genome editing in plants directed by CRISPR/Cas ribonucleoprotein complexes [J]. Hereditas(Beijing), 2020, 42(6): 556-564.
[6]	Ruiying Qin, Pengcheng Wei. Prime editing creates a novel dimension of plant precise genome editing [J]. Hereditas(Beijing), 2020, 42(6): 519-523.
[7]	Xinping Yang,Yuan Yu,Cao Xu. De novo domestication to create new crops [J]. Hereditas(Beijing), 2019, 41(9): 827-835.
[8]	Jue Wang, Juan Huang, Rui Xu. Seamless genome editing in Drosophila by combining CRISPR/Cas9 and piggyBac technologies [J]. Hereditas(Beijing), 2019, 41(5): 422-429.
[9]	Yaoqiang Huang,Guoling Li,Huaqiang Yang,Zhenfang Wu. Progress and application of genome-edited pigs in biomedical research [J]. Hereditas(Beijing), 2018, 40(8): 632-646.
[10]	Caijiao Liang, Fanmei Meng, Yuncan Ai. CRISPR/Cas systems in genome engineering of bacteriophages [J]. Hereditas(Beijing), 2018, 40(5): 378-389.
[11]	Xiaoling Tong,Chunyan Fang,Tingting Gai,Jin Shi,Cheng Lu,Fangyin Dai. Applications of the CRISPR/Cas9 system in insects [J]. Hereditas(Beijing), 2018, 40(4): 266-278.
[12]	Jiawei Liu,Tao Hong,Xin Qin,Yingmin Liang,Ping Zhang. Recent advance on genome editing for therapy of β-hemoglobinopathies [J]. Hereditas(Beijing), 2018, 40(2): 95-103.
[13]	Honghua Li,Gang Liu. The application of CRISPR/Cas9 in genome editing of filamentous fungi [J]. Hereditas(Beijing), 2017, 39(5): 355-367.
[14]	Sanyuan Ma,Qingyou Xia. Genetic breeding of silkworms: from traditional hybridization to molecular design [J]. Hereditas(Beijing), 2017, 39(11): 1025-1032.
[15]	Dingyuan Liu, Ting Qiu, Xiaohui Ding, Miaomiao Li, Muyuan Zhu, Junhui Wang. Rapid construction of multiple sgRNA vectors and knockout of the Arabidopsis IAA2 gene using the CRISPR/Cas9 genomic editing technology [J]. Hereditas(Beijing), 2016, 38(8): 756-764.